or Try an Advanced Search...

    Technical Analysis for ELEV - Elevation Oncology, Inc.

    Grade Last Price % Change Price Change
    D 0.61 5.66% 0.03
    ELEV closed up 0.19 percent on Wednesday, November 20, 2024, on 41 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to find support at its 50 day moving average.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Up
    Historical ELEV trend table...
    Date Alert Name Type % Chg
    20 DMA Resistance Bearish 5.66%
    50 DMA Support Bullish 5.66%
    Stochastic Buy Signal Bullish 5.66%
    NR7 Range Contraction 5.66%
    Narrow Range Bar Range Contraction 5.66%
    Up 3 Days in a Row Strength 5.66%
    Oversold Stochastic Weakness 5.66%
    Crossed Above 50 DMA Bullish 5.86%
    Oversold Stochastic Weakness 5.86%
    MACD Bearish Signal Line Cross Bearish 11.64%
    Older End-of-Day Signals for ELEV ...

       Recent Intraday Alerts

    Alert Time
    Rose Above 10 DMA about 3 hours ago
    10 DMA Resistance about 4 hours ago
    Up 5% about 4 hours ago
    20 DMA Support about 4 hours ago
    2x Volume Pace about 4 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    ELEV Chart by TradingView
    Basic chart:

    Profile

    Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically-defined patient populations in the United States. Its lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. The company was incorporated in 2019 and is based in New York, New York.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Cancer Clinical Medicine Life Sciences Immunology Health Sciences Pharmacy Treatment Of Cancer Monoclonal Antibody Advanced Solid Tumors Duligotuzumab

    Is ELEV a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 6 Elevation Oncology GAAP EPS of -$0.22 misses by $0.02
    Nov 6 Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements
    Oct 10 What Makes Elevation Oncology (ELEV) a New Strong Buy Stock
    Oct 9 Empery Asset Management's Strategic Acquisition in Elevation Oncology
    Sep 23 Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2
    Sep 3 Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    Aug 7 Elevation Oncology reports data from Phase I trial of EO-3021 for solid tumours
    Aug 6 Elevation Oncology: Proving That No One Knows How To Interpret Early-Stage Clinical Results
    Aug 6 Elevation Oncology GAAP EPS of -$0.18
    Aug 6 Elevation Oncology falls after early-stage data for lead cancer drug
    See more ELEV news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.8299
    52 Week Low 0.4401
    Average Volume 740,450
    200-Day Moving Average 2.47
    50-Day Moving Average 0.58
    20-Day Moving Average 0.59
    10-Day Moving Average 0.60
    Average True Range 0.05
    RSI (14) 48.19
    ADX 19.57
    +DI 22.22
    -DI 22.19
    Chandelier Exit (Long, 3 ATRs) 0.56
    Chandelier Exit (Short, 3 ATRs) 0.69
    Upper Bollinger Bands 0.68
    Lower Bollinger Band 0.50
    Percent B (%b) 0.46
    BandWidth 29.47
    MACD Line -0.01
    MACD Signal Line -0.01
    MACD Histogram -0.0002
    Fundamentals Value
    Market Cap 24.65 Million
    Num Shares 42.4 Million
    EPS -2.03
    Price-to-Earnings (P/E) Ratio -0.29
    Price-to-Sales 0.00
    Price-to-Book 1.97
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.62
    Resistance 3 (R3) 0.62 0.60 0.61
    Resistance 2 (R2) 0.60 0.59 0.60 0.61
    Resistance 1 (R1) 0.59 0.59 0.60 0.59 0.61
    Pivot Point 0.58 0.58 0.58 0.58 0.58
    Support 1 (S1) 0.57 0.57 0.57 0.57 0.55
    Support 2 (S2) 0.55 0.56 0.55 0.55
    Support 3 (S3) 0.54 0.55 0.55
    Support 4 (S4) 0.54